Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
by Zacks Equity Research
Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Tabula Rasa Healthcare (TRHC) Catches Eye: Stock Up 9.5%
by Zacks Equity Research
Tabula Rasa Healthcare, Inc. (TRHC) shares rose around 10% in the last trading session.
Aetna's (AET) $1 Billion Notes Due 2047 Rated By A.M Best
by Zacks Equity Research
Rating Giant A.M Bests assigned a Long-Term Issue Credit Rating of "bbb" to Aetna's (AET) $1 billion, 3.875% senior notes due to mature on Aug 15, 2047.
Envision Healthcare Hurt by High Debt, Increasing Expenses
by Zacks Equity Research
Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.
Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Community Health Sells 2 Texas Units, Streamlines Business
by Zacks Equity Research
Community Health Systems, Inc.'s (CYH) subsidiaries have sold their ownership interest in two Texas hospitals and their associated assets to subsidiaries of HCA Healthcare.
Amedisys (AMED) Prospects Impressive Amid Tough Competition
by Zacks Equity Research
On Jun 5, we issued an updated research report on leading molecular diagnostic company, Amedisys, Inc. (AMED).
Why Is Amedisys (AMED) Up 4% Since the Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 47 cents per share in the first quarter of 2017, up 42.4% year over year.
Healthcare Q1 Earnings Slated on May 2: AET, HCA & More
by Zacks Equity Research
The healthcare sector has been in the limelight since the change of power at the White House.
Amedisys (AMED) Poised on Strong Home Health, Risks Remain
by Zacks Equity Research
On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).
Amedisys to Buy East Tennessee to Expand in Personal Care
by Zacks Equity Research
Amedisys Inc. (AMED) recently signed a definitive agreement to buy substantially all of the assets of a Knoxville, TN-based personal care provider, East Tennessee Personal Care Service.
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay
by Zacks Equity Research
On Mar 02, we issued an updated research report on renowned home health and hospice services provider Amedisys Inc. (AMED).
Tenet Healthcare (THC) to Divest Operations to Amedisys
by Zacks Equity Research
Tenet Healthcare Corporation (THC) recently announced that it has inked a deal with Amedisys, Inc. (AMED) to divest its Home Health and Hospice operations in Arizona, Illinois, Massachusetts and Texas to the latter
Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session
by Zacks Equity Research
Amedisys, Inc. (AMED) moved big last session, as its shares rose over 6% on the day.
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
by Zacks Equity Research
Amedisys Inc. (AMED), a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC).
Amedisys (AMED) Earnings Top Q4 Estimates, Revenues Lag
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 44 cents per share in the fourth quarter of 2016, up 10% year over year.
Amedisys' Unit to Buy Personal Care Provider, Home Staff
by Zacks Equity Research
Amedisys, Inc. (AMED) recently decided to buy a Massachusetts-based personal care provider, Home Staff, LLC.
Amedisys Down on Dismal Quarter, Reimbursement Headwind
by Zacks Equity Research
On Dec 8, we issued an updated research report on Baton Rouge, LA-based Amedisys Inc. (AMED).
5 Best Healthcare Bargain Stocks to Buy
by David Bartosiak
Healthcare stocks have been beaten down by the market, you need to buy these STAT!
Your Best Stocks Will Be in the Best Industries
by Kevin Matras
Getting into one of the top Zacks Ranked Industries will increase your odds of success by 2 to 1. Highlighted stocks include ALDW, AMED, BCC, FLWS and HNI.